CClinicalTrials.gg
CompletedNCT06279143dOCT-pBCCUpdated May 26, 2026

The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes

An observational study in BCC - Basal Cell Carcinoma, BCC and Skin Diseases, sponsored by Vejle Hospital. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Vejle Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
210
Ages
18 Years and older
Sex
All
01

Study summary

The purpose is to investigate the diagnostic value (sensitivity and specificity) of dermal-Optical Coherence Tomography (D-OCT, VivoSight Dx), in patients with clinically suspected BCC lesions inside the periocular region and compare these results to previous reports using D-OCT in diagnosing lesions outside the periocular area.

The Hypotheses:

  • The sensitivity and specificity of D-OCT in diagnosing BCC inside the periocular region is comparable to previous reports on BCC lesions outside the periocular region when the standard D-OCT probe is used.
  • The sensitivity and specificity of D-OCT in diagnosing BCC inside the periocular region is increased when the customised D-OCT probe is used.
  • The sensitivity and specificity of D-OCT in diagnosing periocular BCC is comparable to punch biopsy when both standard and the customised D-OCT probes are used.
  • D-OCT with the 10 and 20-millimeter standoff is capable of subtyping periocular BCC.
  • The inter-observer variation in diagnosing and sub-typing periocular BCC decreases with increasing experience in the scanning procedure.
  • The number of scans to correctly interpret D-OCT decreases with increasing experience in the scanning procedure.
  • Delineation of periocular BCC tumour extension is possible using both D-OCT probes
02

Conditions studied

  • BCC - Basal Cell Carcinoma
  • BCC
  • Skin Diseases
  • Eyelid Tumor
  • Eyelid Diseases

Keywords

  • Carcinoma, Basal Cell* / diagnostic imaging
  • Carcinoma, Basal Cell* / pathology
  • Carcinoma, Basal Cell* / surgery
  • Neoplasm, Glandular and epithelial
  • Skin neoplasm
  • Diagnostic imaging
  • Sensitivity and Specificity
  • Tomography, Optical Coherence* / methods
  • Skin Neoplasm* / surgery
  • Neoplasm recurrence
  • Eyelids / pathology
  • Skin diseases
  • Periocular
  • BCC
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive enrolment of newly referred patients under the diagnosis "clinically suspected BCC" in the periocular area

Inclusion criteria

  • Clinically suspected periocular BCC.
  • Biopsy-verified BCC
  • Clinically suspected relapse of periocular BCC
  • Age more than 18 years at baseline.
  • Legally competent, able to give verbal and written consent
  • Communicate in Danish verbally as well as in writing
  • Willingness to participate and able to give informed consent and can comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Anatomical circumstances that make OCT-scanning impossible, i.e., extensive scarring of eyelids, or large ulcerating crusts that hampers scanning
  • Unwillingness to undergo a skin biopsy or excision of lesion.
  • Inability to sign informed consent.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
210 participants (actual)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of D-OCT in diagnosing BCC inside the periocular region, compared to previous reports on lesions outside the periocular region

    To assess if the sensitivity and specificity of D-OCT in diagnosing BCC inside the periocular region is comparable to previous reports on BCC lesions outside the periocular region using the standard probe

    Time frame: March 2024-August 2026

Secondary outcomes

  1. Comparative diagnostic accuracy of D-OCT´s standard vs customized probe for diagnosing BCC

    To compare the sensitivity and specificity of each D-OCT probe for diagnosing periocular BCC, with reference to punch biopsy results.

    Time frame: March 2024-August 2026

  2. Comparative diagnostic accuracy of D-OCT´s standard vs customized probe for subtyping BCC

    To compare the sensitivity and specificity of each D-OCT probe for subtyping periocular BCC, with reference to punch biopsy results.

    Time frame: March 2024-August 2026

  3. Observer agreement in identifying presence/absence of BCC lesions, using D-OCT

    This measure, assesses the consistency among observers in identifying the presence or absence of BCC lesions through the utilization of D-OCT imaging.

    Time frame: March 2024-August 2026

  4. Observer agreement in classifying BCC lesions into subtypes, using D-OCT

    This measure, evaluates the level of agreement among observers in categorizing BCC lesions into specific subtypes based on D-OCT imaging. Potential diagnostic features from lesion types will be tested.

    Time frame: March 2024-August 2026

  5. Observer agreement in mapping BCC lesions prior to surgery, using D-OCT

    This measure, examines the agreement among observers in accurately mapping the extension of BCC lesions prior to surgery with the assistance of D-OCT imaging.

    Time frame: March 2024-August 2026

  6. Quantification of learning curve in correctly diagnosing BCC over time with increasing experience with D-OCT

    This measure, quantifies the improvement in skills over time among observers in diagnosing BCC lesions using D-OCT imaging. It aims to determine the rate at which observers become adept at interpreting D-OCT images for BCC diagnosis.

    Time frame: March 2024-August 2026

  7. Quantification of learning curve in correctly identifying BCC subtypes over time with increasing experience with D-OCT

    This measure, quantifies the improvement in skills over time among observers in accurately identifying different subtypes of BCC lesions using D-OCT imaging. It aims to determine the rate at which observers become adept at interpreting D-OCT images for BCC subtyping.

    Time frame: March 2024-August 2026

  8. Quantification of skills in correctly demarcating BCC over time with increasing experience with D-OCT

    This measure, quantifies the improvement in skills over time among observers in precisely delineating the borders of BCC lesions prior to surgery using D-OCT imaging. It assesses the improvement in demarcation accuracy with increasing experience.

    Time frame: March 2024-August 2026

  9. Accuracy of D-OCT in delineation of periocular BCC extension prior to surgery

    Evaluation af sensitivity of D-OCT imaging in delineation (mapping) of periocular BCC tumour extension - comparing findings with visible boundaries and histopathological diagnosis (considered the gold standard)

    Time frame: March 2024-August 2026

06

Study locations

1 site
  • Department of Ophthalmology, University Hospital of Southern Denmark, Vejle Hospital
    Vejle, Region of Southern Danmark 7100, Denmark
07

Registry details

Key details

Study ID
NCT06279143
Lead sponsor
Vejle Hospital
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Apr 4, 2024
Primary completion
Mar 11, 2026
Completion
May 22, 2026
Last update
May 26, 2026

Study contacts

Flemming Møller, Assoc.prof.
study director · Vejle Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion